Introduction and objectives: International Diabetes Federation (IDF) estimates that worldwide there are 415 million adults aged 20-79 with diabetes mellitus (DM). Although diabetes mellitus (DM) is a highly prevalent disease, only a handful of studies have examined the neuromuscular function in diabetic patients. Even more surprising is this data, if we think that neuromuscular blockade (NMB) is an essential part in the induction and maintenance of general anesthesia. NMB is induced by neuromuscular blocking agents (NMBA). The aim of this review is to update the knowledge of neuromuscular blockade in diabetes mellitus and its implications in clinical practice.